Single-agent Capecitabine as Metronomic Chemotherapy in LAHNSCC (CMHN)
Head and Neck Squamous Cell CarcinomaThe purpose of this study is to investigate whether the addition of metronomic capecitabine to the standard treatment can improve prognosis in locoregionally advanced head and neck squamous cell carcinoma.
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients
Oral Squamous Cell CarcinomaNeoadjvant Therapy2 moreTo evaluate the efficacy of neoadjuvant anti-PD-1 plus anti-VEGFR therapy for patients with locally advanced and resectable oral squamous cell carcinoma, and the CPS>10 in the biopsy samples.
A Study of Docetaxel for Injection (Albumin-bound) in Combination With Nivolumab in Patients With...
Squamous Cell Carcinoma of Head and NeckThis trial is a single-arm, multicenter phase Ib/II clinical study to evaluate the efficacy and safety of Docetaxel for Injection (Albumin-bound) combined with Nivolumab and the pharmacokinetic characteristics of Docetaxel in patients with recurrent or metastatic SCCHN who are positive for PD-L1 expression and have progressed on or after platinum-based therapy.
Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC
Head and Neck Squamous Cell CarcinomaThis study is a single arm phase II trial including 53 patients with T2N2-3M0、T3-4N0-3M0(III-IV) head and neck squamous cell carcinoma (HNSCC) eligible for resection, who receive neo-adjvuant Camrelizumab combined with cisplatin and Nab-paclitaxel. This proposed study will evaluate the efficacy and safety of preoperative administration of Camrelizumab combined with chemotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC) who are about to undergo surgery.
Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell CarcinomaThe goals of this clinical study are to learn about the safety, tolerability, dosing and effectiveness of the study drug, magrolimab in combination with other anticancer therapies in patients with head and neck squamous cell carcinoma (HNSCC).
Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma
Head and Neck Squamous Cell CarcinomaThis is a prospective, open-labelled study to evaluate the efficacy and safety of camrelizumab combined with apatinib mesylate in the induction treatment of patients with locally advanced head and neck squamous cell carcinoma who were judged surgically unresectable or appropriate for non-surgical definitive therapy. The objective response rate (ORR) and safety will be evaluated as the primary endpoints, the 2-year overall survival (OS) rate and progression free survival (PFS) rate will be the second endpoints.
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With...
Head and Neck Squamous Cell CarcinomaSquamous Cell Carcinoma of Anal Canal10 moreThe investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.
Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive...
Cancer of the Head and NeckOropharynx Cancer2 moreThis trial will explore giving standard dose chemotherapy and radiation therapy to sites of disease including all lymph nodes involved with HPV-positive oropharyngeal cancer, but administer lower doses of radiation therapy to the lymph nodes that are not known to be involved with cancer. By doing so, it is hypothesized that there will be equally good long term loco-regional and distant disease control but will reduced long term treatment side effects and improved quality of life in persons living well beyond their cancer treatment.
Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients
Head and Neck Squamous Cell CarcinomaThe purpose of this study is to determine anti-tumor activity by measuring overall response rate in recurrent and/or metastatic HNSCC patients receiving the combination of metformin and pembrolizumab.
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high...
MSI-H Colorectal CancerMelanoma29 moreThis is an open-label, parallel group, non-randomized, multicenter phase II study to evaluate the efficacy of spartalizumab (cohorts 1 and 2) and tislelizumab (cohort 3) in monotherapy in patients with PD1-high-expressing tumors.